Mode
Text Size
Log in / Sign up
Phase 3 Completed N=87 Randomized Single-blind Treatment

Efficacy and Safety of 0.25% Timolol Gel in Healing Surgical Open Wounds

Wound of Skin · Wound Heal · Wound Open · Surgical Wound
Source: ClinicalTrials.gov NCT03452072 ↗
Enrolled (actual)
87
Serious AEs
0.0%
Results posted
May 2026
Primary outcomePrimary: Number of Participants With Re-epithelialization at 30 Days Post op — 9; 12 participants — p=0.580
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

The use of topical beta-blockers, such as 0.25% timolol, in promoting wound healing is currently emerging in the academic literature. The investigators will enroll 114 patients who have their skin cancer surgically removed resulting in open surgical wounds less or equal to 1.5 cm. The objective of this randomized safety study is to determine the safety and efficacy of 0.25% timolol in promoting wound healing in open surgical wounds less or equal to 1.5 cm.

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Re-epithelialization at 30 Days Post op
9; 12 0.580
SECONDARY
Cosmetic Outcomes of Open Surgical Wound Healing by Blinded Physician Vancouver Scar Scale Assessment
8.8; 8.8
SECONDARY
Study Subject Complete the Patient Scar Assessment Via Visual Analogue Scale
5.71; 5.97
SECONDARY
Number of Participants Whose Side Effects Are Associated With 0.25% Topical Timolol for Open Surgical Wounds
1; 0

Eligibility Criteria

Inclusion Criteria

  • Age greater than 18 years
  • Open surgical wound ≤1.5cm
  • No hypersensitivity with use of 0.25% timolol gel

Exclusion Criteria

  • Age less than 18 years of age
  • Open surgical wound >1.5cm
  • Pregnant women
  • Use of systemic retinoids within 1 month
  • Any hypersensitivity with use of 0.25% timolol gel
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03452072). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search